AzTrials
AzTrials

Adrenocortical InsufficiencyNCT01053754

Optimization of the Evaluation of the Adrenal Function After Discontinuation of a Prolonged Therapy With Corticosteroids

A study testing "long" synacthen stimulation test in people with Adrenocortical Insufficiency, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The study (forward-looking and opened) will concern 70 subjects having had a systemic prolonged treatment with corticosteroids for intestinal chronic inflammatory disease, recruited in the services of gastroenterology and endocrinology of the North Hospital of Marseille (France). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Adrenocortical Insufficiency
What is being tested?
"long" synacthen stimulation test
Type of treatment
Injection or infusion
How many people
10 participants
Where
1 siteFrance
Study dates
Jan 2010to Jul 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Intestinal chronic inflammatory diseases (Crohn's disease, chronic ulcerative colitis)
  • Systemic prolonged treatment with corticosteroids during 2 months at least
  • Discontinuation of the treatment with corticosteroids for 6 weeks
  • Basal plasma cortisol between 8 and 20 µg / dl (220 to 550 nmol / l).

Who cannot join

  • Systemic prolonged treatment with corticosteroids because of an other disease than a intestinal chronic inflammatory disease
  • Pregnancy, breast feeding
  • Hypersensibility to synacthene
  • Basal plasma cortisol lower than 8 µg / dl (220 nmol / l) or superior to 20 µg / dl (550 nmol / l)

Trial locations and contacts

1 site in 1 country.

France1 site
  • Assistance Publique-Hopitaux de Marseille

    Marseille, France

Other trials in France

About this study

The study (forward-looking and opened) will concern 70 subjects having had a systemic prolonged treatment with corticosteroids for intestinal chronic inflammatory disease, recruited in the services of gastroenterology and endocrinology of the North Hospital of Marseille (France). The primary objective of the study is to estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard. Indeed, this long test could be realized in ambulatory conditions, and turn out more contributory than the definitive standard to estimate the capacities of answer of the adrenal glands in front of a prolonged stress, as it is the case during a surgical procedure for example.

The secondary objectives are: 1) to determine the relation between the value of basal cortisol and the peak of stimulation of cortisol during short and long tests. This could allow to clarify better the conditions in which it is absolutely necessary to realize a dynamic test, 2) to determine the relation between cortisol assay in the plasma and in the saliva. The sample of saliva is simple and non-invasive, and presents the advantage to be able to be realized in ambulatory conditions and by the patient himself.

The cortisonic withdrawal syndrome is another complication which can arise when a prolonged corticosteroid therapy is discontinued. Clinically, it looks like a chronic adrenocortical insufficiency, but with normal ranges of plasma cortisol. It is probably in touch with a physical dependence to the taking of above physiological doses of GC over a long period. Its physiopathology remains badly known, but could bring in a deficit of secretion of DHEA-S (dehydro-epiandrosterone sulphate), another hormone secreted by the adrenal glands. One of the secondary objectives of the study will consist in informing the variations of DHEA-S after a prolonged corticotherapy, in the basal state and after stimulation by the long synacthen stimulation test.

Read the detailed description

Synthetic glucocorticoids (GC) are used in the treatment of numerous inflammatory or auto-immune diseases, in particular the intestinal chronic inflammatory diseases (Crohn's disease, chronic ulcerative colitis). In case of discontinuation of a prolonged (superior to 3-4 weeks) and systemic treatment, deleterious side effects are frequent, with in particular a risk of adrenocortical insufficiency and withdrawal cortisonic syndrome. Our protocol of medical research concerns these two complications, and aims at optimizing the evaluation of the adrenal function.

The adrenocortical insufficiency after prolonged corticotherapy is the most frequent cause of secondary adrenocortical insufficiency. It is due to the braking of the hypothalamo-pituitary-adrenal (HPA) axis which controls the endogenous secretion of cortisol. It is mostly transient, but can last several months, and exposes to a risk of acute decompensation. An adapted coverage with replacement doses of hydrocortisone (natural GC) is thus necessary during the treatment discontinuation, together with regular hormonal revaluations to track down the recovery of the adrenal function. These evaluations are based on biological measurements, because of the absence of specific clinical symptoms. At first, basal plasma cortisol at 08:00 am (physiological peak of the hormone) is assayed. A value lower than 8 µg / dl (220 nmol / l) allows to do the positive diagnosis of adrenal insufficiency and a value superior to 20 µg / dl (550 nmol / l) to exclude it. Between these 2 values, a doubt remains on the capacities of the adrenal glands to secrete enough cortisol in case of stress, and the realization of a dynamic test of stimulation is then necessary. The standard test used in common practice is the "short" synacthene stimulation test (fragment 1-24 of the ACTH, the hormone secreted by the pituitary gland and stimulating the secretion of cortisol) using an IV injection of 250 µg of immediate synacthen. The study (forward-looking and opened) will concern 70 subjects having had a systemic prolonged treatment with corticosteroids for intestinal chronic inflammatory disease, recruited in the services of gastroenterology and endocrinology of the North Hospital of Marseille (France). The primary objective of the study is to estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard. Indeed, this long test could be realized in ambulatory conditions, and turn out more contributory than the definitive standard to estimate the capacities of answer of the adrenal glands in front of a prolonged stress, as it is the case during a surgical procedure for example.

The secondary objectives are: 1) to determine the relation between the value of basal cortisol and the peak of stimulation of cortisol during short and long tests. This could allow to clarify better the conditions in which it is absolutely necessary to realize a dynamic test, 2) to determine the relation between cortisol assay in the plasma (classically used) and in the saliva ( which is validated for the evaluation of the other adrenal pathology as the Cushing's syndrome, but not still in the adrenocortical insufficiency after prolonged corticotherapy). The sample of saliva is simple and non-invasive, and presents the advantage to be able to be realized in ambulatory conditions and by the patient himself.

The cortisonic withdrawal syndrome is another complication which can arise when a prolonged corticosteroid therapy is discontinued. Clinically, it looks like a chronic adrenocortical insufficiency, but with normal ranges of plasma cortisol. It is probably in touch with a physical dependence to the taking of above physiological doses of GC over a long period. Its physiopathology remains badly known, but could bring in a deficit of secretion of DHEA-S (dehydro-epiandrosterone sulphate), another hormone secreted by the adrenal glands. One of the secondary objectives of the study will consist in informing the variations of DHEA-S after a prolonged corticotherapy, in the basal state and after stimulation by the long synacthen stimulation test.

Being tested
"long" synacthen stimulation test
Keywords
adrenocortical insufficiency, prolonged corticotherapy
Medical subject headings
Addison Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • "long" synacthen stimulation testBiological

    IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard.

    Measured: 2 years

Secondary outcomes (1)
  1. To determine the relation between the value of basal cortisol and the peak of stimulation of cortisol during short and long tests - to determine the relation between cortisol assay in the plasma and in the saliva

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2010 (estimated)
  2. Study startJan 2010
  3. Primary completionJul 2012
  4. Study completionJul 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01053754
Sponsor's protocol ID
2009/23
Other IDs
2009-015730-30, 2009
Status last verified
Aug 2014
First submitted
18 Jan 2010
Last updated
29 Aug 2014
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing "long" synacthen stimulation test in people with Adrenocortical Insufficiency, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 29 Aug 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early. Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard. (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in